Ireland
--:--IST
Active, not recruiting Early Phase 1

CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma

NCT06813417 · tracked via the Priya Life Science Canada tracker
Phase
Early Phase 1
Started
2025-01-30
Last updated
2025-04-10

Condition(s) studied

SarcomaAlveolar Soft Part Sarcoma (ASPS)

Investigational drug(s) / intervention(s)

GCAR1 →

GCAR1: GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. Following infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance3.

Study summary

A single patient study to determine whether GCAR1 is safe and effective for re-treatment of alveolar soft part sarcoma (ASPS) with GPNMB surface expression that has relapsed and is not responding to usual treatment.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The patient must provide informed consent * Adequate organ function, defined as creatinine clearance \>30 ml/min and LVEF \>45% Exclusion Criteria: * Any active uncontrolled infection * Pregnancy or nursing * Anti-cancer therapy within 21 calendar days prior to the first dose of lymphodepleting chemotherapy. If subject has received anti-cancer therapy, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy as per the discretion of the Qualified Investigator/Co-Investigator

Primary outcome measure(s)

  • Treatment Response — Diagnostic imaging (CT and/or MRI) will be performed at baseline (pre-treatment) and then subsequently at 4-6 weeks after GCAR1 infusion, and at 3 months, 6 months, 9 months and 1 year after last infusion to evaluate response to therapy.
    The overall response assessment considers the response of the target and non-target lesions and development of new lesions. Response Classification of Target Lesions, CNS lesions and Non-Target Lesions * Complete response (CR): * Partial response (PR): * Progressive disease (PD): * Stable disease (SD):

Trial sites (1)

FacilityCityRegionStatus
Arthur J.E. Child Comprehensive Cancer Centre Calgary Alberta
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06813417 on ClinicalTrials.gov ↗ ← All trials in Canada